Enriched Honey With Soluble Fiber and Polyphenols on Satiety and Dyslipidemia (SACIMIEL)

Nutritional and Clinical Trial to Evaluate the Effect of a Modified Honey With Soluble Fiber and Polyphenols Consumption in Subjects With Overweight/Obesity and Dyslipidemia

The aim of this trial is to evaluate the possible benefits on saciety and dyslipidemia in subjects with overweight/obesity (BMI ≥25 y <40 kg / m2) and dyslipemia after consumption of a modifed honey with soluble fiber and polyphenols.

Some studies have shown the contribution of high-fiber foods in the reduction of the cardiovascular risk. Besides, polyphenols have reported with their potent antioxidant effect and their implication lowering the vardiovascular risk.

Study Overview

Detailed Description

The trial was designed as a randomized, parallel, double-blind and controlled study with 2 experimental arms. This study was performed to evaluate the effect on saciety and dyslipidemia of subjects with overweight/obesity after a long consumption (3 months) of a modified honey with soluble fiber and polyphenols. Additionally, a short-term randomized, cross-over, doble-blind and controlled trial was also performed to evaluate immediate saciety effect on the same subjects.

For the middle-term study, investigators included 67 participants (8 men and 59 women) between 18 and 65 years (BMI ≥25 and <40 kg / m2). All volunteers were randomized into 2 study groups, and participants received the 2 different study products during the 3 months. On the other hand, the associated short-term trial included 10 participants (5 men and 5 women) between 18 and 65 years (BMI ≥25 and <40 kg / m2). All volunteers were randomized into 2 study groups, and participants took the 2 different study products in two non-consecutive days.

Study Type

Interventional

Enrollment (Actual)

56

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Madrid, Spain, 28046
        • Institute for Health Research IdiPAZ

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Men and women from 18 to 65 years old.
  • Body Mass Index (BMI) ≥25 and <40 kg/m2.
  • Cardiovascular risk <10% to 10 years measured by REGICOR.
  • Total cholesterol ≥ 200 mg/d and at least 2 factors included in the following list:

    • ≥ 45 years or women ≥ 55 years.
    • Family history of cardiovascular disease (CVD) in first degree male relative less than 55 years of age and less than 65 years in women.
    • HDL cholesterol: men <40 or women <50.
    • Triglycerides ≥ 150mg/dL and <200 mg/dL
    • LDL cholesterol ≥ 130mg/dL and < 160mg/dL
    • Smoker
  • Willingness to follow a healthy and balanced hypocaloric diet with mandatory physical activity
  • Social or familiar environment that prevents from accomplishing the dietary treatment
  • Adequate cultural level and understanding for the clinical trial.
  • Signed informed consent

Exclusion Criteria:

  • Body Mass Index (BMI) <25 and ≥40 kg/m2.
  • Individuals diagnosed with Diabetes Mellitus type 1 or 2.
  • Individuals with dyslipidemia on pharmacological treatment.
  • Individuals with hypertension on pharmacological treatment.
  • Individuals diagnosed with eating disorders.
  • Individuals fructose-intolerant.
  • Individuals with a diagnosis of celiac disease or a gluten intolerance.
  • Individuals with severe chronic diseases (hepatic, kidney, …)
  • Individuals receiving a pharmacological treatment that modifies the lipid or glucose profile.
  • Individuals who have participated in the last 3 months in a program or clinical trial to lose weight.
  • Individuals with mental illness.
  • Smokers wanting to stop to smoke during the period that clinical trial lasts.
  • Individuals with high alcohol consumption (> 2-3 servings/ day in men and> 1 serving/day in women (1 serving = 1 glass of wine or 1 bottle of beer).
  • Individuals with large weight fluctuations of more than 4 kg or who have undergone in six months a weight loss diet.
  • Individuals with sensory problems.
  • Individuals with gastrointestinal diseases that affect the digestion or absorption of nutrients.
  • Individuals under pharmacological treatment for losing weight unless treatment is suspended 30 days before the start of the trial.
  • Subjects with intense physical activity.
  • Subjects with food allergies to meals included in breakfast, study product or lunch or that reject their consumption
  • Pregnant or breastfeeding women.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Control honey

Orange blossom honey.

Middle term trial: 40g/day for 3 months in two daily intakes of 20 g/day.

Short term trial: 20g/day in a single day.

Control honey defined as orange blossom honey. Intake daily for 3 months (40 g/day)
Honey modified with soluble fiber and polyphenols, with same organoleptic conditions as control honey. Intake daily for 3 months (40 g/day)
Experimental: Modified honey with soluble fiber and polyphenols

Honey modified with soluble fiber and polyphenols

Middle term trial: 40g/day for 3 months in two daily intakes of 20 g/day.

Short term trial: 20g/day in a single day.

Control honey defined as orange blossom honey. Intake daily for 3 months (40 g/day)
Honey modified with soluble fiber and polyphenols, with same organoleptic conditions as control honey. Intake daily for 3 months (40 g/day)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from Baseline Satiety Hunger Assessment
Time Frame: Day 1, 2

Visual Analogue Scale (VAS). 100mm horizontal line anchored at each end with the extremes of the subjective feeling to be quantified. Subjects are instructed to rate the sensation being experienced according to how they define the line.

e.g., "not at all hungry" (0mm) and "as hungry as I have ever felt" (100mm). Multiple measures are taken at repeated time intervals described below.

Day 1, 2

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from Baseline Lipid Metabolism Parameters
Time Frame: Week 1,12
Cholesterol, LDL-C, HDL-C, TG
Week 1,12
Amount of food consumed in a "food ad libitum"
Time Frame: Day 1, 2
120 min After eating the study product
Day 1, 2
Total amount of food consumed in 24h
Time Frame: Day 1, 2; Week 1, 6, 12
24h Food Record Method
Day 1, 2; Week 1, 6, 12
Change from Baseline Glucose Metabolism Parameters
Time Frame: Day 1, 2; Week 1, 12
Glucose
Day 1, 2; Week 1, 12
Anthropometric Parameters
Time Frame: Day 1, 2; Week 1, 12
Weight and height will be combined to report BMI in kg/m2
Day 1, 2; Week 1, 12
Sensory Perception Test
Time Frame: Day 1, 2; Week 6, 12
Questionnaire of analysis of sensory perception of the food study product. Five questions that are valued on a scale of 0% to 100% asking about the taste and smell of the study product: desire with which the product is taken, taste, smell, consistency and what wait for effectiveness.
Day 1, 2; Week 6, 12
Adverse Effects
Time Frame: Day 1, 2; Week 6, 12
Gastrointestinal Symptoms (Nausea, Diarrhea, Bloating and other disorders)
Day 1, 2; Week 6, 12

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 14, 2019

Primary Completion (Actual)

April 19, 2019

Study Completion (Actual)

September 3, 2019

Study Registration Dates

First Submitted

September 12, 2019

First Submitted That Met QC Criteria

November 5, 2019

First Posted (Actual)

November 6, 2019

Study Record Updates

Last Update Posted (Actual)

November 6, 2019

Last Update Submitted That Met QC Criteria

November 5, 2019

Last Verified

September 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dyslipidemias

Clinical Trials on Control honey

3
Subscribe